Rozenberg S, Joris A, Albert V, Antoine C, Vandromme J
Service de Gynécologie-Obstétrique, CHU Saint-Pierre, ULB.
Rev Med Brux. 2018;39(4):259-263.
Postmenopausal hormone therapy (MHT) is mainly used for the relief of menopausal symptoms. It can also be prescribed for the treatment of postmenopausal osteoporosis, but nowadays, other medications are given to older patients for this indication. Current, available data, demonstrates that MHT is beneficial as well as safe for postmenopausal, symptomatic women. Modern regimens of MHT comprise lower dosages of estrogens than in the past, either safer progestins or SERMs. These regimens should be the preferred option for women with a uterus. Non-androgenic progestin may present reduced thrombotic and breast cancer risks, and transdermal oestrogen could have a reduced thrombotic risk. Oestrogen-only therapy is the preferred option for women who underwent a hysterectomy. Vaginal oestrogen therapy is indicated for women with atrophic vaginitis and recurrent urinary tract infections.
绝经后激素治疗（MHT）主要用于缓解绝经症状。它也可用于治疗绝经后骨质疏松症，但如今，针对这一适应症，其他药物被用于老年患者。目前可得的数据表明，MHT对有症状的绝经后女性既有益又安全。现代MHT方案所使用的雌激素剂量低于过去，采用了更安全的孕激素或选择性雌激素受体调节剂（SERM）。对于有子宫的女性，这些方案应是首选。非雄激素性孕激素可能会降低血栓形成和患乳腺癌的风险，经皮雌激素可能会降低血栓形成风险。对于接受过子宫切除术的女性，仅使用雌激素治疗是首选。阴道雌激素治疗适用于患有萎缩性阴道炎和复发性尿路感染的女性。
